Publications by authors named "L Nikolaenko"
Article Synopsis
- bRT before CAR T-cell therapy for LBCL is gaining traction, but its impact on treatment outcomes is unclear.
- A study analyzed 23 LBCL patients who underwent bRT followed by CAR T-cell therapy, focusing on various PET scan metrics to measure tumor response.
- Results revealed that significant decreases in SUV and MTV during bRT were linked to better progression-free survival, freedom from distant progression, and local control.
- The findings suggest that greater cytoreduction via bRT may enhance the effectiveness of subsequent CAR T-cell therapy in treating large B-cell lymphoma.
Article Synopsis
- BV (brentuximab venetoclax) is an antibody-drug conjugate effective in treating relapsed or refractory Hodgkin lymphoma, but most patients develop resistance over time, a major unmet need in treatment.
- A phase 1 study tested the combination of BV and cyclosporine in patients who had become resistant to BV, focusing on safety, tolerability, and determining the maximum tolerated dose (MTD).
- Out of 29 patients enrolled, the study found a complete response rate of 27% and an overall response rate of 64%, but it had to halt early due to unacceptable toxicity, with treatment-related deaths in three patients.
Hematopoietic cell transplantation (HCT) and chimeric antigen receptor (CAR)-T cell patients are immunocompromised, remain at high risk following SARS-CoV-2 infection, and are less likely than immunocompetent individuals to respond to vaccination. As part of the safety lead-in portion of a phase 2 clinical trial in patients post HCT/CAR-T for hematological malignancies (HM), we tested the immunogenicity of the synthetic modified vaccinia Ankara-based COVID-19 vaccine COH04S1 co-expressing spike (S) and nucleocapsid (N) antigens. Thirteen patients were vaccinated 3-12 months post HCT/CAR-T with two to four doses of COH04S1.
View Article and Find Full Text PDFFludarabine/cyclophosphamide (Flu/Cy) is established for lymphodepletion (LD) prior to standard-of-care CAR T-cell therapy for lymphoma. There is ongoing need to test alternative LD regimens to preserve efficacy, improve safety, and address challenges including the recent national fludarabine shortage. We retrospectively evaluated outcomes among patients with relapsed/refractory aggressive B-cell lymphoma who received bendamustine (n = 27) or Flu/Cy (n = 42) LD before axicabtagene ciloleucel (axi-cel) at our institution.
View Article and Find Full Text PDFOutcomes after programmed death-1 (PD-1) blockade in B-cell lymphomas are disappointing with few durable responses. Histone deacetylase inhibitors exhibit favorable immunomodulatory effects and demonstrate synergistic anti-tumor immune responses with anti-PD-1 therapy in preclinical models. We, therefore, developed a phase I study to evaluate the safety and preliminary efficacy of pembrolizumab with vorinostat in relapsed/refractory B-cell lymphomas.
View Article and Find Full Text PDF